Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia
Saudi Arabia is undergoing a massive healthcare transformation to fulfill its new, national “Vision 2030.” To align with this objective, Saudi Arabia is establishing a new, independent and evidence-based health technology assessment (HTA) entity to help it maximize health gains through efficient use...
Main Authors: | Hussain Abdulrahman Al-Omar, Abdulaziz Abdulhadi Attuwaijri, Ibrahim Abdulrahman Aljuffali |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Saudi Pharmaceutical Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016420300840 |
Similar Items
-
Value drivers for pharmaceutical products in health technology assessment (HTA) in Saudi Arabia: Results from a capacity Building, Multi-Stakeholder workshop
by: Hussain A. Al-Omar, et al.
Published: (2021-09-01) -
Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia
by: Essam A. Tawfik, et al.
Published: (2022-01-01) -
Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines
by: Abdulrahman A. Halwani, et al.
Published: (2023-08-01) -
Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review
by: Mirza AH, et al.
Published: (2023-07-01) -
Drug shortages in Najran region, Saudi Arabia: A cross-sectional survey
by: Hamad S. Alyami, et al.
Published: (2023-05-01)